NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Larimar Therapeutics, Inc. (LRMR) Stock Analysis

Larimar Therapeutics, Inc. (LRMR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LRMR

$3.83

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LRMR with… →

LRMR Key Statistics

As of Sep 4, 2026
Trading
Open
$3.82
Previous Close
$3.83
Day's Range
3.79–3.85
52-Week Range
2.72–6.42
Volume
391.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$397.87M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.00
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$165.67M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.88M
1-Year Return
−1.03%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.88M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LRMR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.52%
2025−1.55%
2024−14.95%
2023+10.17%
2022−61.72%
2021−49.60%
2020+60.74%
2019−77.58%
2018+7.14%
2017+45.28%
2016 (partial year)−0.93%

As of September 4, 2026.

LRMR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$165.67M—
2024$0.00−$80.60M—
2023$0.00−$36.95M—
2022$0.00−$35.36M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$172.50M−$165.67M—
2024$0.00—−$90.89M−$80.60M—
2023$0.00—−$41.76M−$36.95M—
2022$0.00—−$36.53M−$35.36M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LRMR Valuation vs Biotechnology Median

Median of 656 stocks
MetricLRMRBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Larimar Therapeutics, Inc. (LRMR) is capitalised at $397.87M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 71.

The most recent close on file for LRMR is $3.83, dated September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $2.72 to $6.42. The latest close sits 41.07% above that 52-week low.

Financial Health

In fiscal 2025, Larimar Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $165.67M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.75. Annualized volatility over the trailing 10 years is 87.79%. The trailing one-year price return is −1.03%. Across 10 years the annualized return works out at −19.94%.

Growth & Income

No dividend is on file for LRMR.

So far in 2026 the price is +0.52%. Across the complete calendar years on file, 2020 returned +60.74% and 2019 returned −77.58%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Larimar Therapeutics, Inc. (LRMR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Larimar Therapeutics, Inc. LRMR $397.87M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Larimar Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Visit website →